Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

• Published in: The lancet oncology Vol. 23; no. 8; pp. 1031 - 1043
• Main Authors: Tam, Constantine S, Brown, Jennifer R, Kahl, Brad S, Ghia, Paolo, Giannopoulos, Krzysztof, Jurczak, Wojciech, Šimkovič, Martin, Shadman, Mazyar, Österborg, Anders, Laurenti, Luca, Walker, Patricia, Opat, Stephen, Chan, Henry, Ciepluch, Hanna, Greil, Richard, Tani, Monica, Trněný, Marek, Brander, Danielle M, Flinn, Ian W, Grosicki, Sebastian, Verner, Emma, Tedeschi, Alessandra, Li, Jianyong, Tian, Tian, Zhou, Lei, Marimpietri, Carol, Paik, Jason C, Cohen, Aileen, Huang, Jane, Robak, Tadeusz, Hillmen, Peter
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.08.2022; Elsevier Limited
• Subjects: Adverse events; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Bendamustine Hydrochloride; Cardiac arrhythmia; Chronic lymphocytic leukemia; Clinical trials; Comorbidity; COVID-19; Diarrhea; Enzyme inhibitors; Hematology; Hematology, Oncology, and Palliative Medicine; Humans; Hypertension; Immunotherapy; Kinases; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - pathology; Lymphoma; Monoclonal antibodies; Neutropenia; Oral administration; Patients; Piperidines; Protein-tyrosine kinase; Pyrazoles; Pyrimidines; Remission (Medicine); Rituximab; Sequoia; Surface area; Survival; Targeted cancer therapy; United States > US

Zanubrutinib is a next-generation, selective Bruton tyrosine kinase inhibitor with efficacy in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). We compared zanubrutinib with bendamustine–rituximab to determine its effectiveness as frontline therapy in patients with C...